A research team says they have developed a trial HIV vaccine that is able to neutralize dozens of strains of the virus from around the world in animals, according to a new study published in Nature Medicine Monday. The vaccine, the product of a team at the National Institutes of Allergy and Infectious Diseases (NIAID), targets a peptide in the virus' entry machinery.
Why it matters: Great strides have been made in improving the lives of those infected with the HIV virus — nearly 37 million people around the world — but researchers have been unable to develop an effective vaccine. Also, the rate of transmission remains high.
"One of the last holy grails of HIV research is the development of an HIV vaccine."— Anthony Fauci, director, NIAID